Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Doxil in Metastatic Breast Cancer
NCT00005991Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 1997
- Primary completion
- Feb 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and doxorubicin in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate, Duration of Response and 2 more. Started Aug 1997; status: completed.
02
Drugs
gemcitabinedoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00005991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005991.